It's becoming a bit of a broken record, but the refrain "another challenging month" does apply to the current market environment. There were a host of factors influencing stocks and keeping their value down in June. However,with careful selection investors can use the current volatility to make money. You see, there are plenty of fundamentally strong yet undervalued companies that the mainstream investment community hasn't picked up.

Which stocks fit the bill? Take a look at three undervalued stock buys to see:

eResearchTechnology (NASDAQ: ERES) provides technology and services to the pharmaceutical, biotechnology and medical device industries. The company streamlines the clinical trials process by enabling customers to automate the collection, analysis and distribution of data in all phases of clinical development. The firm's flagship product, EXPeRT, processes and interprets electrocardiogram data collected during trials, to insure cardiac safety. eResearchTechnology operates in the US and the UK.

The firm pleased investors earlier in the week, when it reported Q1 EPS of 11 cents and revenues of $33.7 million. Wall Street analysts had been looking for nine cents and $31.6 million. Management also guided Q2 EPS to 10-12 cents (ten cent Street), Q2 revenues to $34-$36 million ($32.95M Street), FY08 EPS to 44-49 cents (44 cent Street) and FY08 revenues to $133-$140 million ($134.99M Street). Friedman Billings subsequently reiterated its "outperform" rating on the shares and boosted its price target to $18.

eResearchTechnology (NASDAQ: ERES) provides technology and services to the pharmaceutical, biotechnology and medical device industries. The company streamlines the clinical trials process by enabling customers to automate the collection, analysis and distribution of data in all phases of clinical development. The firm's flagship product, EXPeRT, processes and interprets electrocardiogram data collected during trials, to insure cardiac safety. eResearchTechnology operates in the US and the UK.

The firm pleased investors late last month, when it reported Q4 EPS of ten cents and revenues of $28.9 million. Wall Street analysts had been looking for eight cents and $28.6 million. Management also guided Q1 EPS to 8-10 cents (nine cent Street view), Q1 revenues to $31-$33 million ($29.6M Street), FY08 EPS to 42-46 cents (41 cent Street) and FY08 revenues to $130-$137 million ($122.1M Street).